Savanne Beekman
Overview
Explore the profile of Savanne Beekman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapeau D, Beekman S, Piet A, Li L, de Ridder C, Stuurman D, et al.
Bioconjug Chem
. 2024 Oct;
35(11):1823-1834.
PMID: 39395152
The main challenges of conventional chemotherapy lie in its lack of selectivity and specificity, leading to significant side effects. Using a small-molecule drug conjugate (SMDC) ensures specific delivery of a...
2.
Chapeau D, Beekman S, Handula M, Murce E, de Ridder C, Stuurman D, et al.
EJNMMI Radiopharm Chem
. 2024 May;
9(1):44.
PMID: 38775990
Background: Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single dual-labeled tracer ensures consistency in both imaging modalities. However, developing...
3.
Murce E, Spaan E, Beekman S, van den Brink L, Handula M, Stuurman D, et al.
Pharmaceuticals (Basel)
. 2023 Aug;
16(8).
PMID: 37630990
Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is conjugated to a targeting vector, for specific delivery to the tumor site. This promising approach can be translated...
4.
Chapeau D, Koustoulidou S, Handula M, Beekman S, de Ridder C, Stuurman D, et al.
Pharmaceuticals (Basel)
. 2023 Jul;
16(7).
PMID: 37513897
Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with...
5.
Handula M, Beekman S, Konijnenberg M, Stuurman D, de Ridder C, Bruchertseifer F, et al.
EJNMMI Radiopharm Chem
. 2023 Jun;
8(1):13.
PMID: 37389800
Background: The [Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist,...
6.
Murce E, Ahenkorah S, Beekman S, Handula M, Stuurman D, de Ridder C, et al.
Pharmaceuticals (Basel)
. 2023 Jun;
16(6).
PMID: 37375829
Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic radionuclides, a theranostic pair possessing almost similar biodistribution...
7.
Murce E, Beekman S, Spaan E, Handula M, Stuurman D, de Ridder C, et al.
Molecules
. 2023 May;
28(10).
PMID: 37241763
Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer. Optimization of the available agents is desirable to improve tumor uptake and reduce...
8.
Koustoulidou S, Handula M, de Ridder C, Stuurman D, Beekman S, de Jong M, et al.
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145375
Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due...